Analysis of structure-based virtual screening studies and characterization of identified active compounds

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 603-613

  Ripphausen, Peter ^a   Stumpfe, Dagmar ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CRYSTALLOGRAPHY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; LIGANDS; MODELS, MOLECULAR; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859468933     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.18     Document Type: Article

References (64)

1. Ripphausen P, Nisius B, Bajorath J. State-of-The-art in ligand-based virtual screening. Drug Discov. Today 16(9-10), 372-376 (2011).
2. Geppert H, Vogt M, Bajorath J. Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation. J. Chem. Inf. Model 50(2), 205-216 (2010).
3. Lyne P. Structure-based virtual screening: An overview. Drug Discov. Today 7(20), 1047-1055 (2002).
4. Villoutreix BO, Eudes R, Miteva MA. Structure-based virtual ligand screening: Recent success stories. Comb. Chem. High Throughput Screen. 12(10), 1000-1016 (2009).
5. Polgar T, Keseru GM. Structure-based virtual screening. Front. Drug Des. Discov. 3(1), 477-502 (2007).
6. Ripphausen P, Nisius B, Peltason L, Bajorath J. Quo vadis, virtual screening? A comprehensive survey of prospective applications. J. Med. Chem. 53(24), 8461-8467 (2010).
7. Schneider G, Böhm H-J. Virtual screening and fast automated docking methods. Drug Discov. Today 7(1), 64-70 (2002).
8. Doman TN, McGovern SL, Witherbee BJ et al. Molecular docking and high-Throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45(11), 2213-2221 (2002). (Pubitemid 34525801)
9. Wang S, Milne GWA, Yan X et al. Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. J. Med. Chem. 39(10), 2047-2054 (1996). (Pubitemid 26163253)
10. Schuster D, Nashev LG, Kirchmair J et al. Discovery of nonsteroidal 17b-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J. Med. Chem. 51(14), 4188-4199 (2008). (Pubitemid 352032443)
11. Perez-Pineiro R, Burgos A, Jones DC et al. Development of a novel virtual screening protocol to identify potential trypanothione reductase inhibitors. J. Med. Chem. 52(6), 1670-1680 (2009).
12. Markowitz J, Chen I, Gitti R et al. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J. Med. Chem. 47(21), 5085-5093 (2004). (Pubitemid 39314906)
13. Kenyon V, Chorny I, Carvajal WJ, Holman TR, Jacobson MP. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J. Med. Chem. 49(4), 1356-1363 (2006). (Pubitemid 43271887)
14. Cavasotto CN, Phatak SS. Homology modeling in drug discovery: Current trends and applications. Drug Discov. Today 14(13-14), 676-683 (2009).
15. Lipinski CA, Lombardo F, Dominy BW, Feeney BJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23(1-3), 3-25 (1997). (Pubitemid 27046991)
16. Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. J. Med. Chem. 49(20), 5851-5855 (2006). (Pubitemid 44484931)
17. Seifert MHJ. Targeted scoring functions for virtual screening. Drug Discov. Today 14(11-12), 562-569 (2009).
18. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 10(7), 464-469 (2005).
19. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discov. 2(4), 469-488 (2007). (Pubitemid 47073073)
20. Hopkins AL, Groom CR, Alex A. Ligand efficiency: A useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004). (Pubitemid 38510559)
21. Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8(19), 876-877 (2003). (Pubitemid 37194496)
22. Shen J, Tan C, Zhang Y et al. Discovery of potent ligands for estrogen receptor b by structure-based virtual screening. J. Med. Chem. 53(14), 5361-5365 (2010).
23. Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene pim-1 kinase. J. Med. Chem. 51(6), 1972-1975 (2008). (Pubitemid 351438879)
24. Cozza G, Bonvini P, Zorzi E et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application. J. Med. Chem. 49(8), 2363-2366 (2006).
25. Peach ML, Tan N, Choyke SJ et al. Directed discovery of agents targeting the met tyrosine kinase domain by virtual screening. J. Med. Chem. 52(4), 943-951 (2009).
26. Katritch V, Jaakola V-P, Lane JR et al. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. J. Med. Chem. 53(4), 1799-1809 (2010).
27. Zhao L, Brinton RD. Structure-based virtual screening for plant-based ERbselective ligands as potential preventative therapy against age-related neurodegenerative diseases. J. Med. Chem. 48(10), 3463-3466 (2005). (Pubitemid 40664095)
28. Taylor JC, Bock CW, Takusagawa F, Markham GD. Discovery of novel types of inhibitors of S-adenosylmethionine synthesis by virtual screening. J. Med. Chem. 52(19), 5967-5973 (2009).
29. Herschhorn A, Hizi A. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. J. Med. Chem. 51(18), 5702-5713 (2008).
30. Mizutani MY, Itai A. Efficient method for high-Throughput virtual screening based on flexible docking: Discovery of novel acetylcholinesterase inhibitors. J. Med. Chem. 47(20), 4818-4828 (2004). (Pubitemid 39238256)
31. Knox AJS, Meegan MJ, Sobolev V et al. Target specific virtual screening: optimization of an estrogen receptor screening platform. J. Med. Chem. 50(22), 5301-5310 (2007). (Pubitemid 350057842)
32. Carlsson J, Yoo L, Gao Z-G et al. Structure-based discovery of A2A adenosine receptor ligands. J. Med. Chem. 53(9), 3748-3755 (2010).
33. Golub AG, Yakovenko OY, Bdzhola VG et al. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J. Med. Chem. 49(22), 6443-6450 (2006). (Pubitemid 44657440)
34. Zhong S, Chen X, Zhu X et al. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J. Med. Chem. 51(15), 4553-4562 (2008).
35. Brenk R, Naerum L, Grädler U et al. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J. Med. Chem. 46(7), 1133-1143 (2003). (Pubitemid 36428219)
36. Cherkasov A, Ban F, Santos-Filho O et al. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. J. Med. Chem. 51(7), 2047-2056 (2008). (Pubitemid 351503260)
37. Caporuscio F, Rastelli G, Imbriano C, Del Rio A. Structure-based design of potent aromatase inhibitors by high-Throughput docking. J. Med. Chem. 54(12), 4006-4017 (2011).
38. Khanfar MA, Hill RA, Kaddoumi A, El Sayed KA. Discovery of novel GSK-3b inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. J. Med. Chem. 53(24), 8534-8545 (2010).
39. Barreca ML, De Luca L, Iraci N et al. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model. 47(2), 557-562 (2007). (Pubitemid 46615957)
40. Sopkova-de Oliveira Santos J, Lesnard A, Agondanou J-H et al. Virtual screening discovery of new acetylcholinesterase inhibitors issued from CERMN chemical library. J. Chem. Inf. Model. 50(3), 422-428 (2010).
41. Ren J-X, Li L-L, Zheng R-L et al. Discovery of novel pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. J. Chem. Inf. Model. 51(6), 1364-1375 (2011).
42. Barril X, Brough P, Drysdale M et al. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med. Chem. Lett. 15(23), 5187-5191 (2005). (Pubitemid 41463644)
43. Nolan KA, Timson DJ, Stratford IJ, Bryce RA. In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg. Med. Chem. Lett. 16(24), 6246-6254 (2006). (Pubitemid 44709905)
44. Yang H, Dou W ,Lou J, Leng Y, Shen J. Discovery of novel inhibitors of 11b-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Bioorg. Med. Chem. Lett. 18(4), 1340-1345 (2008). (Pubitemid 351246683)
45. McLean LR, Zhang Y, Degnen W et al. Discovery of novel inhibitors for DHODH via virtual screening and x-ray crystallographic structures. Bioorg. Med. Chem. Lett. 20(6), 1981-1984 (2010).
46. Richardson CM, Nunns CL, Williamson DS et al. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. Bioorg. Med. Chem. Lett. 17(14), 3880-3885 (2007). (Pubitemid 46920948)
47. Price S, Bordogna W, Bull RJ et al. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-Thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. 17(2), 370-375 (2007). (Pubitemid 46073757)
48. Azim MK, Ahmed W, Khan IA, Rao NA, Khan KM. Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Bioorg. Med. Chem. Lett. 18(9), 3011-3015 (2008). (Pubitemid 351608860)
49. Geldenhuys WJ, Darvesh AS, Funk MO, Van der Schyf CJ, Carroll RT. Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg. Med. Chem. Lett. 20(17), 5295-5298 (2010).
50. Liang Z, Zhang D, Ai J et al. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-met kinase. Bioorg. Med. Chem. Lett. 21(12), 3749-3754 (2011).
51. Xu W, Chen G, Zhu W, Zuo Z. Identification of a sub-micromolar, non-peptide inhibitor of b-secretase with low neural cytotoxicity through in silico screening. Bioorg. Med. Chem. Lett. 20(19), 5763-5766 (2010).
52. Lee K, Kim J, Jeong K-W et al. Structure-based virtual screening of Src kinase inhibitors. Bioorg. Med. Chem. 17(8), 3152-3161 (2009).
53. Endo S, Matsunaga T, Kuwata K et al. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumor maker, AKR1B10. Bioorg. Med. Chem. 18(7), 2485-2490 (2010).
54. Furdas SD, Shekfeh S, Bissinger E-M et al. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg. Med. Chem. 19(12), 3678-3689 (2011).
55. Yang H, Shen Y, Chen J, Jiang Q, Leng Y, Shen J. Structure-based virtual screening for identification of novel 11b-HSD1 inhibitors. Eur. J. Med. Chem. 44(3), 1167-1171 (2009).
56. Zhao H-T, Soda M, Endo S, Hara A, El-Kabbani O. Selectivity determinants of inhibitor binding to the tumor marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. Eur. J. Med. Chem. 45(9), 4354-4357 (2010).
57. Vidovic D, Busby SA, Griffin PR, Schürer SC. A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARg partial agonists. ChemMedChem 6(1), 94-103 (2011).
58. ROCS, version 3.1.2, OpenEye Scientific Software, Inc., Santa Fe, NM, USA, 2009.
59. Rogers D, Hahn M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50(5), 742-754 (2010).
60. Krüger DM, Evers A. Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors. ChemMedChem. 5(1), 148-158 (2010).
61. McGaughey GB, Sheridan RP, Bayly CI et al. Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model. 47(4), 1504-1519 (2007). (Pubitemid 47210053)
62. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucl. Acids Res. 28(1), 235-242 (2000). (Pubitemid 30047768)
63. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45(1), 177-182 (2005). (Pubitemid 40736970)
64. Stumpfe D, Ripphausen P, Bajorath J. Virtual compound screening in drug discovery. Future Med. Chem. 4(5), 613-602 (2012).